Of all medications indicated for use in pregnancy, Diclectin is the most studied in the world in terms of safety and efficacy. It is the only prescription medication approved by Health Canada specifically indicated to treat nausea and vomiting of pregnancy (NVP).
Diclectin® has been prescribed for over 40 years in Canada and has been proven safe and effective for use throughout pregnancy. It is a specially formulated combination of doxylamine succinate (an antihistamine) and pyridoxine hydrochloride (vitamin B6) and has been used by over 35 million women worldwide to treat NVP.
As recently as 2016, a Health Canada Scientific Advisory Panel and the Society of Obstetricians and Gynaecologists of Canada (SOGC) reaffirmed their complete confidence in Diclectin’s safety and efficacy after reviewing its vast body of scientific evidence. In 2013, the FDA approved Diclectin for use in the United States under the name Diclegis®. Diclectin was also approved in Israel in 2015.
As further evidence of Diclectin’s/Diclegis’ safety and efficacy, it is currently recommended as first-line treatment for NVP by Health Canada, the SOGC, the American Congress of Obstetricians and Gynecologists (ACOG) and the Association of Professors of Gynecology and Obstetrics (APGO).
Duchesnay has complete confidence in the safety and efficacy of Diclectin/Diclegis. We remain firmly committed to providing women with safe and effective treatment options for use throughout pregnancy.